LL-37 vs thymosin alpha-1
Last updated: October 27, 2026 · 5 min read · By the Grey Peptides Editorial Board
- Thymosin alpha-1 is an approved drug in about 35 countries, though not in the US 1, with randomised trials in hepatitis and a large sepsis trial that found no survival benefit 7.
- LL-37 is the body's own antimicrobial peptide. Its trials gave it on the skin for leg and foot ulcers, where the larger leg-ulcer trial missed its main goal 12, and by mouth in a recombinant bacterium in one COVID-19 trial 14.
- Neither has been shown to 'boost immunity' in healthy people, and injectable LL-37 is due before an FDA committee by the end of February 2027 1.
Side by side
LL-37 Low and thymosin alpha-1 High sit at opposite ends of our evidence scale. The table is read from our encyclopedia entries.
| Field | LL-37 | Thymosin α1 |
|---|---|---|
| Encyclopedia entry | LL-37 Full entry | Thymosin α1 Full entry |
| Molecule class | Peptide | Peptide |
| Category | Healing & Recovery | Immune |
| FDA status | Research Chemical | Not FDA Approved |
| Approved elsewhere | None recorded | over 35 countries by a 2009 count (PMID 19392576), not the US |
| Evidence grade | Low | High |
| Half-life | Undetermined | ≈ 2 hours |
| Formula | C205H340N60O53 | C129H215N33O55 |
| Molecular weight | 4,493.3 g/mol | 3,108.3 g/mol |
| WADA 2026 | Prohibited (S0 catch-all) | Unsettled (S0 may apply) |
| WADA 2027 | Prohibited (S0 catch-all) | Unsettled (S0 may apply) |
| In one line | The only human cathelicidin — an antimicrobial peptide with direct activity against bacteria, fungi, viruses, and biofilms, with additional roles in wound healing and immune signaling. | A thymic peptide approved as Zadaxin in about 35 countries; its hepatitis trials were mixed, and its largest trial, in 1,106 sepsis patients, found no effect on death. |
| Mechanism | Direct antimicrobial activity via membrane disruption of gram-positive and gram-negative bacteria, fungi, and enveloped viruses. Modulates macrophage polarization, neutralizes LPS, promotes keratinocyte migration, and stimulates angiogenesis via FPRL1 receptor activation. Abnormally elevated in rosacea and some psoriasis phenotypes (pathogenic at high local concentrations). | Modulates both innate and adaptive immunity. Activates TLR2 and TLR9 on dendritic cells and monocytes, driving NF-κB activation and production of IL-12, TNF-α, and IL-6. Promotes dendritic cell maturation, T-cell differentiation (particularly Th1), and enhances NK cell cytotoxicity. Restores immune function in immunocompromised states (hepatitis B/C, sepsis, post-chemotherapy) and enhances vaccine responses in elderly and hemodialysis populations. |
| Sources in the entry | 9 | 23 |
| Study cards | 9 | 16 |
| Dosage page | None | Dosage page |
What each is
Thymosin alpha-1 is a 28-amino-acid peptide. Made synthetically as thymalfasin and sold as Zadaxin, it is approved in about 35 countries, including Italy and China according to our dataset, for chronic hepatitis B and other uses; it is not approved in the US, where it has orphan drug designations 1.
LL-37 is the C-terminal peptide of human cathelicidin (hCAP18). Besides defending against microbes, it attracts immune cells, stimulates blood-vessel growth and promotes tissue repair 2; cells lining the urinary tract release it on contact with bacteria 3. It is not approved anywhere 1.
Thymosin alpha-1's evidence
Thymosin alpha-1 has been tested in randomised trials for decades. In chronic hepatitis B, 98 patients given it for 26 weeks had a complete virological response at 18 months of 40.6%, against 9.4% untreated 4, and added to interferon, loss of a key viral marker at 72 weeks was 45.8% against 28.0%, a difference that did not reach significance (P = 0.067) 5. In hepatitis C, it improved biochemical response when added to interferon 6.
The largest trial was negative. In 2025, a trial across 22 Chinese centres randomised 1,106 adults with sepsis to thymosin alpha-1 or placebo for seven days; 28-day mortality was 23.4% against 24.1%, no meaningful difference 7. Smaller studies in COVID-19 and HIV found no significant benefit on their main measures 8 9. One trial in haemodialysis patients found better antibody responses to an H1N1 vaccine when thymosin alpha-1 was added 10.
LL-37's evidence
LL-37's human trials are topical. In a small double-blind study of 34 people with hard-to-heal venous leg ulcers, the two lower doses of topical LL-37 healed ulcers faster than placebo 11. The larger follow-up, HEAL LL-37, randomised 148 patients, and across the full population LL-37 did not meet its primary endpoint 12. A trial in mildly infected diabetic foot ulcers in Jakarta found improved granulation with an LL-37 cream 13, and a recombinant bacterium delivering LL-37 by mouth was tested in 238 adults hospitalised with COVID-19 14.
LL-37 also has a darker side in research: excess, abnormally processed cathelicidin is implicated in rosacea 15, and in breast cancer tissue its precursor tracked markers of aggressive disease and LL-37 amplified growth signalling 2. An antimicrobial peptide is not automatically safe to inject.
Regulatory and sport status
Neither is FDA-approved 1. Injectable LL-37 is one of the five peptides FDA plans to take to a second Pharmacy Compounding Advisory Committee meeting before the end of February 2027 1; our article on the second PCAC five covers it. Thymosin alpha-1's nomination was withdrawn and FDA's category list (updated May 14, 2026) names it in no category, so it cannot be compounded in the US either 1. Check our WADA status page for the sport status of each.
'Immune boosting' claims
Neither peptide has been tested for 'boosting immunity' in healthy people. Thymosin alpha-1's trials are in people with specific diseases, mostly chronic hepatitis, and its largest trial, in sepsis, was negative 7. LL-37's trials are mostly topical treatments for chronic wounds 12, and excess, abnormally processed cathelicidin is implicated in the skin inflammation of rosacea 15.
How the differences add up (as of October 27, 2026)
Thymosin alpha-1 is a real drug abroad, with positive hepatitis trials and a clearly negative sepsis trial, and no US approval. LL-37 is an endogenous antimicrobial peptide with small topical wound trials, one of which missed its main goal, and unresolved safety questions for injection. If you are considering either, the questions are what condition it is for, what the trials in that condition show, and where the product comes from.
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
No. It is approved as Zadaxin (thymalfasin) in about 35 countries for chronic hepatitis B and other uses, but not in the US.
Does LL-37 work?
It has been tested mainly as a topical treatment for chronic ulcers. A small trial was positive, but the larger 148-patient trial missed its primary endpoint. It has not been tested as an injection.
Which is better for immunity?
Neither has been tested for boosting immunity in healthy people. Thymosin alpha-1's largest trial, in 1,106 people with sepsis, found no survival benefit.
Related on Grey Peptides
Sources
- Grey Peptides dataset records for LL-37 and thymosin alpha-1 (approval and status text: thymosin alpha-1 approved as Zadaxin in about 35 countries, a list the entry has not re-verified, not in the US, in no 503A category; LL-37 not approved, nomination withdrawn, PCAC review by the end of February 2027; sequences; studied doses as sourced on each entry); read October 27, 2026.
- Weber, G., et al. (2009). Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res, 11(1), R6. PMID: 19183447
- Chromek, M., et al. (2006). The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat Med, 12(6), 636-41. PMID: 16751768
- Chien, R. N., et al. (1998). Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology, 27(5), 1383-7. PMID: 9581695
- Lim, S. G., et al. (2006). A randomized, placebo-controlled trial of thymosin-alpha1 and lymphoblastoid interferon for HBeAg-positive chronic hepatitis B. Antivir Ther, 11(2), 245-53. PMID: 16640105
- Sherman, K. E., et al. (1998). Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology, 27(4), 1128-35. PMID: 9537454
- Wu, J., et al. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 388, e082583. PMID: 39814420
- Shehadeh, F., et al. (2023). A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. J Infect Dis, 227(2), 226-235. PMID: 36056913
- Chen, C., et al. (2024). Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV. BMC Infect Dis, 24(1), 97. PMID: 38233816
- Carraro, G., et al. (2012). Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine, 30(6), 1170-80. PMID: 22178096
- Grönberg, A., et al. (2014). Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen, 22(5), 613-21. PMID: 25041740
- Mahlapuu, M., et al. (2021). Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen, 29(6), 938-950. PMID: 34687253
- Miranda, E., et al. (2023). Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res, 315(9), 2623-2633. PMID: 37480520
- Zhao, Y., et al. (2023). Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial. J Med Virol, 95(8), e29035. PMID: 37605995
- Yamasaki, K., et al. (2007). Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med, 13(8), 975-80. PMID: 17676051
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead